keyword
MENU ▼
Read by QxMD icon Read
search

Antiphospholipid in obstetric patient

keyword
https://www.readbyqxmd.com/read/28173738/pregnancy-failure-in-patients-with-obstetric-antiphospholipid-syndrome-with-conventional-treatment-the-influence-of-a-triple-positive-antibody-profile
#1
J O Latino, S Udry, F M Aranda, S D A Perés Wingeyer, D S Fernández Romero, G F de Larrañaga
Conventional treatment of obstetric antiphospholipid syndrome fails in approximately 20-30% of pregnant women without any clearly identified risk factor. It is important to identify risk factors that are associated with these treatment failures. This study aimed to assess the impact of risk factors on pregnancy outcomes in women with obstetric antiphospholipid syndrome treated with conventional treatment. We carefully retrospectively selected 106 pregnancies in women with obstetric antiphospholipid syndrome treated with heparin + aspirin...
January 1, 2017: Lupus
https://www.readbyqxmd.com/read/28164533/possibility-of-coagulation-system-activation-determination-with-tissue-factor-in-pregnancy-complications
#2
Ludek Slavik, Martin Novak, Jana Ulehlova, Martin Prochazka, Jana Prochazkova, Veronika Lattova, Petr Polak, Radovan Pilka
BACKGROUND: In this part of the study, where we determined the causes of preeclampsia and other obstetric complications, we focused on the role of tissue factor (TF) in the activation of these pathophysiological processes. Recent findings attribute a significant part of the activation of coagulation creation of autoantibodies. Once this mechanism is activated, the antibodies induce expression of tissue factor (TF, CD142) on monocytes and vascular endothelial cells. METHODS: We have proposed a monitor activation model of the coagulation system in preeclampsia and other pregnancy complications using TF expression on monocytes by flow cytometry and simultaneous determination the TF-induced thrombin generation in plasma...
October 1, 2016: Clinical Laboratory
https://www.readbyqxmd.com/read/28138914/obstetric-and-perinatal-outcome-in-anti-ro-ssa-positive-pregnant-women-a-prospective-cohort-study
#3
Nuria Martínez-Sánchez, Sergio Pérez-Pinto, Ángel Robles-Marhuenda, Francisco Arnalich-Fernández, María Martín Cameán, Edurne Hueso Zalvide, Jose Luis Bartha
: Anti-Ro/SS-A is one specific type of antinuclear antibodies. They are in the majority of cases associated with primary Sjögren syndrome (SS) but also in Systemic Lupus Erythematosus (SLE), rheumatoid arthritis (RA), and in healthy people. During pregnancy, they are mainly associated to congenital heart block (CHB) and neonatal lupus (NL). The aim of this study was to compare the rate of maternal and fetal complications between a series of anti-Ro/SS-A positive pregnant women prospectively followed...
January 30, 2017: Immunologic Research
https://www.readbyqxmd.com/read/28126966/obstetric-antiphospholipid-syndrome-early-variations-of-angiogenic-factors-are-associated-with-adverse-outcomes-the-noh-angio-observational-cohort-study
#4
Éva Cochery-Nouvellon, Érick Mercier, Sylvie Bouvier, Jean-Pierre Balducchi, Isabelle Quéré, Antonia Perez-Martin, Eve Mousty, Vincent Letouzey, Jean-Christophe Gris
The prognostic value of angiogenic factors in newly pregnant women with obstetric antiphospholipid syndrome has not been documented. We observed 513 obstetric antiphospholipid syndromes who experienced three consecutive spontaneous abortions before the 10th week of gestation or one fetal loss at or beyond the 10th week. We assessed the plasma concentrations of the proangiogenic factor placenta growth factor and of the antiangiogenic factor soluble fms-like tyrosine kinase-1 on the eve and on the 4th day of the low-molecular weight heparin-low dose aspirin treatment...
January 25, 2017: Haematologica
https://www.readbyqxmd.com/read/28120818/pregnancy-and-menopause-in-patients-with-systemic-lupus-erythematosus-and-or-antiphospholipid-syndrome-practical-guide-from-eular
#5
Roberta Vagelli, Chiara Tani, Marta Mosca
Over the last few decades, in reproductive medicine have allowed an improvement in the management and outcome of pregnancy in connective tissue diseases (CTD), such as Systemic progress Lupus Erythematosus and Antiphospholipid Syndrome; however, pregnancy and other related issues represent a crucial moment for patients and their family and some unmet needs are still present. In routine clinical practise, health professionals involved in the care of SLE and/or APS patients need to consider many aspects of the reproductive life of patients, involving not only pregnancy and family planning but also fertility, contraception, cancer surveillance and menopause...
January 25, 2017: Polskie Archiwum Medycyny Wewnętrznej
https://www.readbyqxmd.com/read/28028298/microrna-expression-in-antiphospholipid-syndrome-a-systematic-review-and-microrna-target-genes-analysis
#6
S Muhammad Shazwan, M Muhammad Aliff, A A Asral Wirda, A R Hayati, M Maizatul Azma, A R Nur Syahrina, A H Nazefah, S Jameela, M M Nur Fariha
INTRODUCTION: Antiphospholipid antibodies (aPL) are autoantibodies that attack phospholipid through anti-beta 2-glycoprotein 1. The actions of aPL are associated with events leading to thrombosis and morbidity in pregnancy. Antiphospholipid syndrome (APS) is diagnosed when a patient is persistently positive for aPL and also has recognised clinical manifestations such as recurrent pregnancy losses, arterial or venous thrombosis and in a catastrophic case, can result in death. Unfortunately, the pathogenesis of APS is still not well established...
December 2016: Malaysian Journal of Pathology
https://www.readbyqxmd.com/read/28000012/evaluation-of-the-clinical-relevance-of-anti-annexin-a5-antibodies-in-chinese-patients-with-antiphospholipid-syndrome
#7
Shulan Zhang, Ziyan Wu, Jing Li, Xiaoting Wen, Liubing Li, Wen Zhang, Jiuliang Zhao, Fengchun Zhang, Yongzhe Li
A hallmark feature of antiphospholipid syndrome (APS) is the presence of antiphospholipid antibodies (aPLs). Few studies have addressed the clinical relevance of anti-annexin A5 antibodies (aANXA5) in Chinese patients with APS. In this study, we evaluated the clinical performance of aANXA5 in the diagnosis of APS. Sera from 313 subjects were tested, including 170 samples from patients with APS, 104 samples from patients with non-APS diseases as disease controls (DC), and 39 healthy controls (HC). Serum IgG and IgM aANXA5 were determined by ELISA...
December 21, 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27816952/antiphosphatidylserine-prothrombin-antibodies-as-biomarkers-to-identify-severe-primary-antiphospholipid-syndrome
#8
Ariela Hoxha, Elena Mattia, Marta Tonello, Chiara Grava, Vittorio Pengo, Amelia Ruffatti
BACKGROUND: Anti-phosphatidylserine/prothrombin (aPS/PT) antibodies have begun to be considered potentional biomarkers for antiphospholipid syndrome (APS). This cohort study investigate the role of aPS/PT antibodies as a risk factor for severe APS by evaluating the association between those antibodies and clinical/laboratory profiles of APS. METHODS: Plasma/serum samples from 197 APS patients, 100 healthy subjects and 106 patients with autoimmune diseases were collected...
November 7, 2016: Clinical Chemistry and Laboratory Medicine: CCLM
https://www.readbyqxmd.com/read/27555120/antiphospholipid-syndrome-and-kidney-disease
#9
REVIEW
Frank Bienaimé, Christophe Legendre, Fabiola Terzi, Guillaume Canaud
The antiphospholipid syndrome is a common autoimmune disease caused by pathogenic antiphospholipid antibodies, leading to recurrent thrombosis and/or obstetrical complications. Importantly for nephrologists, antiphospholipid antibodies are associated with various renal manifestations including large renal vessel thrombosis, renal artery stenosis, and a constellation of intrarenal lesions that has been termed antiphospholipid nephropathy. This last condition associates various degrees of acute thrombotic microangiopathy, proliferative and fibrotic lesions of the intrarenal vessels, and ischemic modifications of the renal parenchyma...
January 2017: Kidney International
https://www.readbyqxmd.com/read/27454295/pravastatin-improves-pregnancy-outcomes-in-obstetric-antiphospholipid-syndrome-refractory-to-antithrombotic-therapy
#10
Eleftheria Lefkou, Apostolos Mamopoulos, Themistoklis Dagklis, Christos Vosnakis, David Rousso, Guillermina Girardi
BACKGROUND: Administration of conventional antithrombotic treatment (low-dose aspirin plus low-molecular weight heparin [LDA+LMWH]) for obstetric antiphospholipid syndrome (APS) does not prevent life-threatening placenta insufficiency-associated complications such as preeclampsia (PE) and intrauterine growth restriction (IUGR) in 20% of patients. Statins have been linked to improved pregnancy outcomes in mouse models of PE and APS, possibly due to their protective effects on endothelium...
August 1, 2016: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/27446342/immunomodulatory-effects-of-therapeutic-plasma-exchange-on-monocytes-in-antiphospholipid-syndrome
#11
Anush Martirosyan, Martin Petrek, Amit Kishore, Gayane Manukyan
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombosis and recurrent fetal loss, with the persistent presence of antiphospholipid antibodies (aPLs). aPLs exert their pathogenic effect via the overproduction of tissue factor and activation of complement and several cell types, including endothelial cells, platelets and notably monocytes. As a result, a hypercoagulable state develops leading to APS-associated obstetric complications and fetal loss. Despite being far from optimal, treatment of APS usually includes heparin and low dose aspirin...
August 2016: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/27432808/persistent-triple-antiphospholipid-antibody-positivity-as-a-strong-risk-factor-of-first-thrombosis-in-a-long-term-follow-up-study-of-patients-without-history-of-thrombosis-or-obstetrical-morbidity
#12
C M Yelnik, G Urbanski, E Drumez, V Sobanski, H Maillard, A Lanteri, S Morell-Dubois, C Caron, S Dubucquoi, D Launay, A Duhamel, E Hachulla, P Y Hatron, M Lambert
INTRODUCTION: The long-term risk of first thrombosis and benefit of prophylaxis in antiphospholipid antibody (aPL) carriers without history of thrombosis or obstetrical morbidity is poorly known. This study aimed to evaluate the long-term rate and risk factors associated with a first thrombosis in those patients. PATIENTS AND METHODS: After a prior study ended in December 2005 and was already published, we extended the follow-up period of our cohort of aPL carriers...
July 17, 2016: Lupus
https://www.readbyqxmd.com/read/27432776/non-conventional-antiphospholipid-antibodies-in-patients-with-clinical-obstetrical-aps-prevalence-and-treatment-efficacy-in-pregnancies
#13
Arsène Mekinian, Marie-Charlotte Bourrienne, Lionel Carbillon, Amélie Benbara, Abisror Noémie, Sylvie Chollet-Martin, Ahmed Tigaizin, Francois Montestruc, Olivier Fain, Pascale Nicaise-Roland
OBJECTIVES: To describe the prevalence of non-conventional APL in patients with obstetrical APS without conventional APL and the impact of treatment on pregnancy outcome. METHODS: Patients with clinical obstetrical criteria were tested for anti-phosphatidylethanolamine (aPE) IgG/M, anti-prothrombin/phosphatidylserine (anti-PS/PT) IgG/M, and anti-annexin V IgG. Pregnancy losses rates were compared between APS, non-conventional APS, and non-APL and in untreated pregnancies to treated ones for each group...
October 2016: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/27421221/antiphospholipid-syndrome
#14
REVIEW
M Khamashta, M Taraborelli, S Sciascia, A Tincani
Antiphospholipid syndrome (APS) is an autoimmune condition characterized by the occurrence of thrombosis (arterial and/or venous), often multiple, and/or pregnancy morbidity. Thrombosis is one of the major disease mechanisms, mainly caused by activating endothelial cells, monocytes, and platelets. At present, the management of APS patients with a history of thrombosis is based on long-term antithrombotic therapy, due to the high rate of recurrent thrombosis (29% per year without treatment). Obstetrical APS includes heterogeneous pregnancy complications whose pathogenesis has been increasingly elucidated in the past years...
February 2016: Best Practice & Research. Clinical Rheumatology
https://www.readbyqxmd.com/read/27406427/antiphospholipid-antibodies-and-associated-clinical-manifestations
#15
M Galli, G Finazzi, T Barbui
The Antiphospholipid Syndrome (APS) is defined by the association between antiphospholipid antibodies, i.e. anticardiolipin (aCL) and/or lupus anticoagulant (LA) antibodies, and one or more of the following clinical manifestations: arterial and venous thrombosis, recurrent abortions and thrombocytopenia (1). Among them, deep venous thromboses, pulmonary embolism and thrombosis of the cerebral arteries are the most frequent events, occurring in approximately 1/3 of the patients. Thrombosis of the placental vessels (2) is considered the cause of the obstetrical complications (recurrent spontaneous abortions, fetal deaths or fetal growth retardation) suffered by approximately 10% of the women with antiphospholipid antibodies (1), whereas a variable degree of thrombocytopenia is reported by about 20-25% of the patients (3)...
1996: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/27401589/inherited-thrombophilia-in-women-with-poor-apl-related-obstetric-history-prevalence-and-outcomes-survey-of-208%C3%A2-cases-from-the-european-registry-on-obstetric-antiphospholipid-syndrome-cohort
#16
Jaume Alijotas-Reig, Raquel Ferrer-Oliveras, Enrique Esteve-Valverde, Amelia Ruffatti, Angela Tincani, Elmina Lefkou, Maria Tiziana Bertero, Gerard Espinosa, Emmanuel Coloma, Sara de Carolis, Patrizia Rovere-Querini, Valentina Canti, Elisa Picardo, Micaela Fredi, Arsene Mekinian
AIM: To analyse the prevalence and effects of inherited thrombophilic disorders (ITD) on maternal-foetal outcomes in cases of antiphospholipid antibody related to obstetric complications. METHODS: Women with obstetric complaints who tested positive for aPL and with inherited thrombophilia were prospectively and retrospectively included. RESULTS: ITD data were available in 208 of 338: 147 had obstetric antiphospholipid syndrome (OAPS) and 61 aPL-related obstetric morbidity (OMAPS)...
August 2016: American Journal of Reproductive Immunology: AJRI
https://www.readbyqxmd.com/read/27370963/proinflammatory-proteins-in-female-and-male-patients-with-primary-antiphospholipid-syndrome-preliminary-data
#17
Mirjana Bećarević, Svetlana Ignjatović
The latest classification criteria for the diagnosis of the antiphospholipid syndrome (APS, an autoimmune disease characterized by thromboses, miscarriages and presence of antiphospholipid antibodies (Abs)) emphasized that thrombotic manifestations of APS should be without any signs of an inflammatory process. However, atherosclerosis (a chronic inflammatory response to the accumulation of lipoproteins in the walls of arteries) and APS are characterized by some similar features. We evaluated whether proinflammatory proteins were associated with the features of the primary APS (PAPS)...
October 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27346975/detection-of-multiple-annexin-autoantibodies-in-a-patient-with-recurrent-miscarriages-fulminant-stroke-and-seronegative-antiphospholipid-syndrome
#18
Philipp Scholz, Markus Auler, Bent Brachvogel, Thomas Benzing, Peter Mallman, Thomas Streichert, Andreas R Klatt
Anti-phospholipid syndrome (APS) is one of the main causes for recurrent miscarriages. The diagnosis of APS is based on the occurrence of clinical symptoms such as thrombotic events or obstetric complications as well as the detection of antiphospholipid antibodies directed against β2-glycoprotein I and cardiolipin, or a positive lupus anticoagulant assay. However, there is a subpopulation of patients with clinical symptoms of APS, but the lack of serological markers (seronegative APS). In addition, a large proportion of patients with unexplained recurrent miscarriages exist...
2016: Biochemia Medica: časopis Hrvatskoga Društva Medicinskih Biokemičara
https://www.readbyqxmd.com/read/27342460/additional-treatments-for-high-risk-obstetric-antiphospholipid-syndrome-a-comprehensive-review
#19
REVIEW
Amelia Ruffatti, Ariela Hoxha, Maria Favaro, Marta Tonello, Anna Colpo, Umberto Cucchini, Alessandra Banzato, Vittorio Pengo
Most investigators currently advocate prophylactic-dose heparin plus low-dose aspirin as the preferred treatment of otherwise healthy women with obstetric antiphospholipid syndrome, whilst women with a history of vascular thrombosis alone or associated with pregnancy morbidity are usually treated with therapeutic heparin doses in association with low-dose aspirin in an attempt to prevent both thrombosis and pregnancy morbidity. However, the protocols outlined above fail in about 20 % of pregnant women with antiphospholipid syndrome...
June 25, 2016: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/27291869/controversies-concerning-the-antiphospholipid-syndrome-in-obstetrics
#20
Dulce María Albertina Camarena Cabrera, Claudia Rodriguez-Jaimes, Sandra Acevedo-Gallegos, Juan Manuel Gallardo-Gaona, Berenice Velazquez-Torres, José Antonio Ramírez-Calvo
Antiphospholipid antibody syndrome is a non-inflammatory autoimmune disease characterized by recurrent thrombotic events and/or obstetric complications associated with the presence of circulating antiphospholipid antibodies (anticardiolipin antibodies, anti-β2 glycoprotein-i antibodies, and/or lupus anticoagulant. Antiphospholipid antibodies are a heterogeneous group of autoantibodies associated with recurrent miscarriage, stillbirth, fetal growth restriction and premature birth. The diversity of the features of the proposed placental antiphospholipid antibodies fingerprint suggests that several disease processes may occur in the placentae of women with antiphospholipid antibody syndrome in the form of immune responses: inflammatory events, complement activation, angiogenic imbalance and, less commonly, thrombosis and infarction...
January 2017: Reumatología Clinica
keyword
keyword
114533
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"